Human Umbilical Cord Mesenchymal Stem Cell Therapy for Patients with Active Rheumatoid Arthritis: Safety and Efficacy
Human Umbilical Cord Mesenchymal Stem Cell Therapy for Patients with Active Rheumatoid Arthritis: Safety and Efficacy
复制标题
DOI：
10.1089/scd.2013.0023
复制
发表时间：
2013-12-15
影响因子：
4
通讯作者：
Liu, Yongjun
中科院分区：
文献类型：
--
作者：
Wang, Liming;Wang, Lihua;Liu, Yongjun
本研究旨在评估人脐带间充质干细胞（UC-MSCs）治疗类风湿关节炎（RA）的安全性和有效性。在这项正在进行的队列研究中，纳入了172例对传统药物治疗反应不足的活动性RA患者。将患者分为两组进行不同的治疗：经静脉注射的疾病缓解抗风湿药物（DMARDs）加不含UC-MSCs的培养基或DMARDs加UC-MSCs组（每次4 × 107个细胞）。记录不良事件和临床信息。进行了血清学标志物检测，以评估安全性和疾病活动性。检测血清炎性趋化因子/细胞因子水平，分析外周血淋巴细胞亚群。输注期间或输注后未观察到严重不良反应。UC-MSCs首次治疗后血清肿瘤坏死因子-α和白细胞介素-6水平下降（P
This study was designed to assess the safety and efficacy of human umbilical cord mesenchymal stem cells (UC-MSCs) in the treatment of rheumatoid arthritis (RA). In this ongoing cohort, 172 patients with active RA who had inadequate responses to traditional medication were enrolled. Patients were divided into two groups for different treatment: disease-modifying anti-rheumatic drugs (DMARDs) plus medium without UC-MSCs, or DMARDs plus UC-MSCs group (4x10(7) cells per time) via intravenous injection. Adverse events and the clinical information were recorded. Tests for serological markers to assess safety and disease activity were conducted. Serum levels of inflammatory chemokines/cytokines were measured, and lymphocyte subsets in peripheral blood were analyzed. No serious adverse effects were observed during or after infusion. The serum levels of tumor necrosis factor-alpha and interleukin-6 decreased after the first UC-MSCs treatment (P